Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
| Autor: | Finn, Richard S., Kudo, Masatoshi, Merle, Philippe, Meyer, Tim, Qin, Shukui, Ikeda, Masafumi, Xu, Ruocai, Edeline, Julien, Ryoo, Baek-Yeol, Ren, Zhenggang, Cheng, Ann-Lii, Galle, Peter R., Kaneko, Shuichi, Kumada, Hiromitsu, Wang, Anran, Mody, Kalgi, Dubrovsky, Leonid, Siegel, Abby B., Llovet, Josep M |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p482-482, 151p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|